MOLLY WOODS: Open Payments
NPI 1710661228 · KANSAS CITY, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,975 in 226 payments from 13 companies in 2025. Trend: 2023 $816 · 2024 $2,117 · 2025 $2,975
Food & beverage: $2,975
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 22 | $384 |
| E.R. Squibb & Sons, L.L.C. | 34 | $382 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 23 | $375 |
| ABBVIE INC. | 38 | $372 |
| Otsuka America Pharmaceutical, Inc. | 24 | $366 |
| Neurocrine BioSciences, Inc. | 16 | $293 |
| Vanda Pharmaceuticals Inc. | 28 | $216 |
| Janssen Pharmaceuticals, Inc | 9 | $168 |
| Axsome Therapeutics, Inc. | 12 | $165 |
| Teva Pharmaceuticals USA, Inc. | 14 | $147 |
Products named: CAPLYTA, COBENFY, VRAYLAR, ARISTADA, INGREZZA, REXULTI, HETLIOZ, Auvelity.
Industry payments across KS — which companies pay providers there.
